Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

SU Jili; ZHOU Xiaoshuang; FAN Xiuzhao; HAO Huiqiang; TIAN Shuangshuang; HUI Dongna; HAN Xiutao

doi:10.16766/j.cnki.issn.1674-4152.003060

Volume 21 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Chinese Journal of General Practice > 2023 > 21(7): 1105-1108

SU Jili, ZHOU Xiaoshuang, FAN Xiuzhao, HAO Huiqiang, TIAN Shuangshuang, HUI Dongna, HAN Xiutao. Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy[J]. Chinese Journal of General Practice, 2023, 21(7): 1105-1108. doi: 10.16766/j.cnki.issn.1674-4152.003060

Citation:

SU Jili, ZHOU Xiaoshuang, FAN Xiuzhao, HAO Huiqiang, TIAN Shuangshuang, HUI Dongna, HAN Xiutao. Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy[J]. Chinese Journal of General Practice, 2023, 21(7): 1105-1108. doi: 10.16766/j.cnki.issn.1674-4152.003060

Citation:

SU Jili, ZHOU Xiaoshuang, FAN Xiuzhao, HAO Huiqiang, TIAN Shuangshuang, HUI Dongna, HAN Xiutao. Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy[J]. Chinese Journal of General Practice, 2023, 21(7): 1105-1108. doi: 10.16766/j.cnki.issn.1674-4152.003060

PDF( 482 KB)

Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

doi: 10.16766/j.cnki.issn.1674-4152.003060

3.
The Fifth Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030000, China

Funds:

202103021222013

Received Date: 2022-09-26
Available Online: 2023-08-28

Abstract

Abstract

Objective To evaluate the effect of cyclophosphamide (CTX) combined with glucocorticoids (GS) in the treatment of primary IgA nephropathy (IgAN) with different degrees of hematuria, and provide reference for therapy of IgAN. Methods The clinical data of the primary IgAN patients treated with CTX and GS at the Shanxi Provincial People's Hospital from January 2015 to December 2021 were retrospectively collected. According to the degree of baseline hematuria, they were divided into mild hematuria group [urinary red blood cell count (URBC) < 30/high-power field (HPF)] and severe hematuria group (URBC≥30/HPF). The changes of renal function before therapy and 1st, 3rd and 6th month after therapy were compared between the two groups. The main outcomes were proteinuria remission rate, estimated glomerular filtration rate (eGFR) slope. The secondary outcomes were serum creatinine (Scr), blood urea nitrogen (BUN), eGFR and adverse reactions. Results A total of 132 IgAN patients were included, 95 cases in the mild hematuria group and 37 cases in the severe hematuria group. After therapy, proteinuria remission rate and eGFR slope in the severe hematuria group were higher than those in the mild hematuria group, and the difference between the two groups was statistically significant (all P < 0.05). Scr in the severe hematuria group showed a downward trend, while that in the mild hematuria group showed an upward trend, and the difference between the groups was statistically significant (P < 0.05). eGFR in both groups showed a trend of decreasing first and then increasing. The change of eGFR in the severe hematuria group was more obvious than that in the mild hematuria group (P < 0.05). BUN in both groups showed a trend of increasing first and then decreasing. The level of BUN in the severe hematuria group was lower than that in the mild hematuria group at all time points (P < 0.05). Conclusion The combination of CTX and GS has a good therapeutic effect on IgAN patients with severe hematuria. The level of hematuria before therapy may be latent basis for the selection of therapy decisions for IgAN.
- IgA nephropathy,
- Cyclophosphamide,
- Glucocorticoids,
- Haematuria,
- Clinical efficacy

FullText(HTML)

References(17)

References

[1]	MAIXNEROVA D, TESAR V. Emerging modes of treatment of IgA nephropathy[J]. Int J Mol Sci, 2020, 21(23): 9064. doi: 10.3390/ijms21239064
[2]	NATALE P, PALMER S C, RUOSPO M, et al. Immunosuppressive agents for treating IgA nephropathy[J]. Cochrane Database Syst Rev, 2020, 3(3): CD003965. DOI: 10.1002/14651858.CD003965.
[3]	范晶, 黄冠文, 包继文, 等. IgA肾病预后相关危险因素分析[J]. 中华全科医学, 2022, 20(5): 731-734, 735. doi: 10.16766/j.cnki.issn.1674-4152.002441 FAN J, HUANG G W, BAO J W, et al. Analysis of risk factors for the prognosis of IgA nephropathy[J]. Chinese Journal of General Practice, 2022, 20(5): 731-734, 735. doi: 10.16766/j.cnki.issn.1674-4152.002441
[4]	Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276.
[5]	YU G Z, GUO L, DONG J F, et al. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study[J]. Am J Kidney Dis, 2020, 76(1): 90-99. doi: 10.1053/j.ajkd.2019.11.008
[6]	LEVEY A S, GANSEVOORT R T, CORESH J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US food and drug administration and european medicines agency[J]. Am J Kidney Dis, 2020, 75(1): 84-104. doi: 10.1053/j.ajkd.2019.06.009
[7]	WONG M G, LV J C, HLADUNEWICH M A, et al. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics[J]. Am J Nephrol, 2021, 52(10-11): 827-836. doi: 10.1159/000519812
[8]	CHEN T Y, LI X, LI Y X, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy[J]. Am J Kidney Dis, 2019, 74(3): 300-309. doi: 10.1053/j.ajkd.2019.02.016
[9]	EBBESTAD R, SANAEI N M, LUNDBERG S. Long-term outcomes of patients with IgA nephropathy categorized by the international IgAN risk prediction tool and by the degree of hematuria at diagnosis[J]. Nephron, 2022, 146(6): 573-583. doi: 10.1159/000525001
[10]	谷晓娟, 王惠芳, 尹文娟, 等. 伴有肉眼血尿的IgA肾病患者临床病理特点及预后分析[J]. 中华全科医师杂志, 2021, 20(5): 581-586. doi: 10.3760/cma.j.cn114798-20200830-00948 GU X J, WANG H F, YIN W J, et al. Clinicopathological characteristics and prognosis of IgA nephropathy patients with gross hematuria[J]. Chinese Journal of General Practitioners, 2021, 20(5): 581-586. doi: 10.3760/cma.j.cn114798-20200830-00948
[11]	LUO R, GUO S M, LI Y Q, et al. Plasma fractalkine levels are associated with renal inflammation and outcomes in immunoglobulin A nephropathy[J]. Nephrol Dial Transplant, 2019, 34(9): 1549-1558. doi: 10.1093/ndt/gfy169
[12]	CORMICAN S, GRIFFIN M D. Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease?[J]. Front Immunol, 2021, 12: 664202. DOI: 10.3389/fimmu.2021.664202.
[13]	PATTRAPORNPISUT P, AVILA-CASADO C, REICH H N. IgA Nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441. doi: 10.1053/j.ajkd.2021.01.024
[14]	陈晓洁, 许日聪, 胡豪飞, 等. 血红蛋白水平与IgA肾病患者肾脏预后的关系[J]. 中华肾脏病杂志, 2021, 37(9): 730-738. doi: 10.3760/cma.j.cn441217-20210120-00108 CHEN X J, XU R C, HU H F, et al. Association between hemoglobin levels and renal progression in patients with IgA nephropathy[J]. Chinese Journal of Nephrology, 2021, 37(9): 730-738. doi: 10.3760/cma.j.cn441217-20210120-00108
[15]	ZHU B, LIU W H, YU D R, et al. The association of low hemoglobin levels with IgA nephropathy progression: a two-center cohort study of 1, 828 cases[J]. Am J Nephrol, 2020, 51(8): 624-634. doi: 10.1159/000508770
[16]	ILIOPOULOU V N, CHARKOFTAKI G, COOPER J C, et al. Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis[J]. J Pharm Pharmacol, 2021, 73(12): 1683-1692. doi: 10.1093/jpp/rgab135
[17]	MA F, YANG X X, ZHOU M L, et al. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide[J]. J Nephrol, 2020, 33(6): 1241-1250. doi: 10.1007/s40620-020-00752-x

Relative Articles

[1]	SONG Jian, CUI Beiyong, ZHU Hongwei. Therapeutic effect of triptorelin combined with recombinant human growth hormone on central precocious puberty in girls[J]. Chinese Journal of General Practice, 2023, 21(9): 1544-1546. doi: 10.16766/j.cnki.issn.1674-4152.003166
[2]	GAO Dai, ZHANG Zhuoli. Concept and development of glucocorticoid application in systemic lupus erythematosus under treat-to-target strategy[J]. Chinese Journal of General Practice, 2023, 21(8): 1279-1283. doi: 10.16766/j.cnki.issn.1674-4152.003102
[3]	GAO Fei, TIAN Miao, LI Guang, DU Ming-zhu, ZHOU Zhi-hui, SONG Yan-ping, DONG Chang-hu. A retrospective clinical study of 9 cases with autoimmune diseases combined acquired hemophilia A[J]. Chinese Journal of General Practice, 2022, 20(10): 1678-1681. doi: 10.16766/j.cnki.issn.1674-4152.002677
[4]	FAN Jing, HUANG Guan-wen, BAO Ji-wen, ZHANG Min-fang, ZHOU Wen-yan, WANG Qin, NI Zhao-hui, WANG Ling. Analysis of risk factors for the prognosis of IgA nephropathy[J]. Chinese Journal of General Practice, 2022, 20(5): 731-734. doi: 10.16766/j.cnki.issn.1674-4152.002441
[5]	MA Guang-xi, ZHANG Jun, YANG Yi-yu, WANG Yu. Clinical effect of platelet lysate on lumbar interbody fusion in elderly patients with lumbar disc herniation[J]. Chinese Journal of General Practice, 2021, 19(12): 2051-2054. doi: 10.16766/j.cnki.issn.1674-4152.002234
[6]	SONG Ming-ze, TANG Yin. Comparison of clinical efficacy between percutaneous nephrolithotripsy and transurethral flexible ureteroscopic lithotripsy in the treatment of renal calculi[J]. Chinese Journal of General Practice, 2021, 19(5): 753-755,766. doi: 10.16766/j.cnki.issn.1674-4152.001908
[7]	TAO Xue-qin, CUI Hui-xin, WANG Da-wei. Clinical efficacy of mouse nerve growth factor on the elderly patients with herpes zoster and variations of serum IgG,IgM and IgA[J]. Chinese Journal of General Practice, 2020, 18(8): 1294-1296,1430. doi: 10.16766/j.cnki.issn.1674-4152.001489
[8]	YAO Huan-yin, MA Lan, DONG Hong, TONG Hai-ming, WANG Xiao-xian, CHEN Xiao-hong, LIU Shu-mei. Clinical significance and expression of glucocorticoid receptor α,β mRNAs in infant wheezing[J]. Chinese Journal of General Practice, 2020, 18(2): 258-261. doi: 10.16766/j.cnki.issn.1674-4152.001220
[9]	ZHANG Yun, YIN Yue, LIU Shu-fen, . Relationship between polymorphism of CYP2C19*2 genotype and cyclophosphamide treatment in systemic lupus erythematosus[J]. Chinese Journal of General Practice, 2019, 17(3): 355-359. doi: 10.16766/j.cnki.issn.1674-4152.000680
[10]	WANG Ming-qi, CHEN Xu, ZHOU Cheng-pei, GAO Hao-ran, QIAN Ji-xian. Advances in Application of Glucocorticoids in Perioperative Degenerative Cervical Myelopathy[J]. Chinese Journal of General Practice, 2019, 17(5): 825-828,833. doi: 10.16766/j.cnki.issn.1674-4152.000802
[11]	LI Xiao-na, LI Yu-jie, YU Min, HUANG Wei, LI Dong-zhi, ZHU Xiao-feng, FAN Kai-hui, ZHAO Zi-bo, MA Qiong-jie. Efficacy of post auricular injection of methylprednisolone on treatment of idiopathic deafness and its effect on hemorheology and plasma Hcy[J]. Chinese Journal of General Practice, 2018, 16(1): 72-74. doi: 10.16766/j.cnki.issn.1674-4152.000021
[14]	BAO Zhijian. Influence of acetylcysteine combined glucocorticoids on immune function and inflammation of patients with severe asthma[J]. Chinese Journal of General Practice, 2017, 15(8): 1429-1432. doi: 10.16766/j.cnki.issn.1674-4152.2017.08.045
[16]	LIU Wen-bin, WU Di-jiong, YE Bao-dong, GAO Yan-ting, YU Qing-hong, SHEN Yi-ping, ZHOU Yu-hong. Recombinant human thrombopoietin in the treatment of secondary immune thrombocytopenia[J]. Chinese Journal of General Practice, 2016, 14(3): 349-351. doi: 10.16766/j.cnki.issn.1674-4152.2016.03.003
[17]	HUANG Wen-hui, WANG Chong-min. Curative effect of TCM medicated bath combined with tacrolimus on moderate to severe atopic dermatitis in children and influence on serum LTB₄ on LTC₄[J]. Chinese Journal of General Practice, 2016, 14(4): 604-606,685. doi: 10.16766/j.cnki.issn.1674-4152.2016.04.030
[18]	SONG Jia-wei, YIN Zhi-qin. Clinical curative effect of continuous blood purification with nursing intervention in the treatment of severe acute pancreatitis[J]. Chinese Journal of General Practice, 2016, 14(7): 1234-1236. doi: 10.16766/j.cnki.issn.1674-4152.2016.07.054
[19]	HE Li-feng, LIU Kai-ming, WANG Zhen. Therapeutic efficacy of cyclophosphamide on thymoma in patients with myasthenia gravis[J]. Chinese Journal of General Practice, 2016, 14(5): 752-753,789. doi: 10.16766/j.cnki.issn.1674-4152.2016.05.018
[20]	LIANG Shi-kai, JIN Juan, GONG Jian-guang, LIN Bo, LI Yi-wen, HE Qiang. Change in the number of autophagosomes in podocyte and its clinical significance in Immunoglobulin A nephropathy[J]. Chinese Journal of General Practice, 2016, 14(12): 1983-1986. doi: 10.16766/j.cnki.issn.1674-4152.2016.12.004

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	古丽鲜·吐尔洪，阿布力米提·阿木提，李敏，坤多姿·玉山江，李光玉. 激素治疗IgA肾病大鼠对骨密度和TLR4信号通路的影响. 现代生物医学进展. 2024(05): 836-840 .
2.	查汗·索林格，李静，刘梦云. 原发性IgA肾病患者伴发高尿酸血症危险因素分析. 新乡医学院学报. 2024(05): 419-422 .
3.	张俊涛，何旭，蒋俊杰. 环磷酰胺治疗肾病综合征对患者ApoA1、ApoB、Lp(a)的影响. 分子诊断与治疗杂志. 2024(12): 2244-2247+2251 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (387) PDF downloads(8)

Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

doi: 10.16766/j.cnki.issn.1674-4152.003060